Latest News for: nk cell

Edit

Alps Group Inc Publishes Clinical Safety, Tolerability and Effectiveness Data Supporting Advancement of Its Autologous NK Cell Pipeline Using an In-House Developed Culture Protocol (Form 6-K) (Alps Group Inc)

Public Technologies 23 Feb 2026
Alps Group Inc Publishes Clinical Safety, Tolerability and Effectiveness Data Supporting Advancement of Its Autologous NK Cell Pipeline Using an In-House Developed Culture Protocol ... The NK cells also ...
Edit

One stem cell generates 14 million tumor-killing NK cells in major cancer breakthrough

Science Daily 18 Feb 2026
... NK cells, including CAR-equipped versions designed to hunt specific cancers.
Edit

IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering ...

Nasdaq Globe Newswire 16 Feb 2026
The iPSC-derived NK cells clinical trial analysis report delivers important insights ...
Edit

NK Cell Therapy Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by ...

GetNews 09 Feb 2026
... Cell Therapy Market ... However, short life span, cumbersome preparation method of CAR NK cells, difficulties with NK cells and other factors are creating obstacles in the Nk Cell Therapy Market growth.
Edit

ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas

Business Wire 02 Feb 2026
... ImmunityBio’s novel, off-the-shelf CD19-targeted high-affinity natural killer (NK) cell therapy .
Edit

A framework integrating multiscale in silico modeling and experimental data predicts CAR-NK cell cytotoxicity across ...

PNAS 30 Jan 2026
SignificancePredicting the activity of chimeric antigen receptor ...
Edit

NK Cell Therapy Market 2034: 7MM Outlook, 30+ Active Developers, IND/NDA Momentum, and Next-Gen CAR-NK ...

GetNews 22 Jan 2026
According to DelveInsight, its NK Cell Therapy Market ... Key Highlights from the NK Cell Therapy Market Report Key NK Cell Therapy Companies are MiNK Therapeutics, Indapta Therapeutics, ImmunityBio, Inc.
Edit

ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy ...

Caledonian Record 16 Jan 2026
CULVER CITY, Calif.--(BUSINESS WIRE)--Jan 16, 2026-- ....
Edit

ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma

Pharmiweb 16 Jan 2026
... control in first four subjects, all administered as outpatient therapy QUILT-106 off-the-shelf CD19 CAR-NK trial is ongoing and represents a next-generation NK cell therapy for Non-Hodgkins Lymphoma.
Edit

GT Biopharma Announces IND Submission for GTB-5550 TriKE�, a B7-H3-targeted natural killer (NK) cell engager ...

Nasdaq Globe Newswire 15 Jan 2026
GT Biopharma targets a portion of the estimated $362 billion global solid tumor market ... .
Edit

Zelluna Completes First GMP Batch of ZI-MA4-1, a Novel TCR-NK Cell Therapy, to Treat Patients ...

Nasdaq Globe Newswire 12 Dec 2025
ZLNA), a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell ...
Edit

New hope for AML: 3D model enhances NK cell therapies (Donau-Universität Krems)

Public Technologies 19 Nov 2025
... system to improve NK cell immunotherapy for acute myeloid leukemia (AML).The aim is to prevent relapses and reduce animal testing with mimicking models.
  • 1

Article Search

tools
×
×
×
×